AU601726B2

AU601726B2 – Adhesive wound dressing
– Google Patents

AU601726B2 – Adhesive wound dressing
– Google Patents
Adhesive wound dressing

Download PDF
Info

Publication number
AU601726B2

AU601726B2
AU71831/87A
AU7183187A
AU601726B2
AU 601726 B2
AU601726 B2
AU 601726B2
AU 71831/87 A
AU71831/87 A
AU 71831/87A
AU 7183187 A
AU7183187 A
AU 7183187A
AU 601726 B2
AU601726 B2
AU 601726B2
Authority
AU
Australia
Prior art keywords
alginate
adhesive
dressing
film
dressing according
Prior art date
1986-04-17
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Expired – Fee Related

Application number
AU71831/87A
Other versions

AU7183187A
(en

Inventor
Rory James Maxwell Smith
Leslie James Squires
Richard John Wiggans
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Johnson and Johnson Hospital Services Inc

Original Assignee
Johnson and Johnson Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
1986-04-17
Filing date
1987-04-21
Publication date
1990-09-20
Family has litigation

First worldwide family litigation filed
litigation
Critical
https://patents.darts-ip.com/?family=10596351&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU601726(B2)
«Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1987-04-21
Application filed by Johnson and Johnson Products Inc
filed
Critical
Johnson and Johnson Products Inc

1987-10-22
Publication of AU7183187A
publication
Critical
patent/AU7183187A/en

1990-09-20
Application granted
granted
Critical

1990-09-20
Publication of AU601726B2
publication
Critical
patent/AU601726B2/en

2007-04-21
Anticipated expiration
legal-status
Critical

Status
Expired – Fee Related
legal-status
Critical
Current

Links

Espacenet

Global Dossier

Discuss

Classifications

A—HUMAN NECESSITIES

A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE

A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES

A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads

A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons

A61L15/42—Use of materials characterised by their function or physical properties

A61L15/58—Adhesives

A—HUMAN NECESSITIES

A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE

A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS

A61F13/00—Bandages or dressings; Absorbent pads

A61F13/02—Adhesive plasters or dressings

A61F13/0203—Adhesive plasters or dressings having a fluid handling member

A61F13/0213—Adhesive plasters or dressings having a fluid handling member the fluid handling member being a layer of hydrocoloid, gel forming material

A—HUMAN NECESSITIES

A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE

A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS

A61F13/00—Bandages or dressings; Absorbent pads

A61F13/02—Adhesive plasters or dressings

A61F13/0203—Adhesive plasters or dressings having a fluid handling member

A61F13/0223—Adhesive plasters or dressings having a fluid handling member characterized by parametric properties of the fluid handling layer, e.g. absorbency, wicking capacity, liquid distribution

A—HUMAN NECESSITIES

A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE

A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES

A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads

A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons

A61L15/42—Use of materials characterised by their function or physical properties

A61L15/60—Liquid-swellable gel-forming materials, e.g. super-absorbents

Abstract

A wound dressing comprises an alginate layer fixed to a plastics backing layer, such as a polyurethane film. The backing layer extends beyond the edges of the alginate layer to provide a marginal portion which is coated with adhesive. Such a dressing may be formed by providing an adhesive-coated plastics film having a lamella releasably attached to its adhesive surface, cutting the lamella into an inner and an outer portion, such that the outer portion surrounds the inner portion, removing the inner portion to expose a region of the adhesive-coated plastics film, and attaching the alginate layer to the exposed region of film.

Description

I- I ~r.
00U «’17 2 COMMONWEALTH OF AUSTRALIA PATENTS ACT 1952 COMPLETE SPECIFICATION FOR OFFICE USE Form Short Title: Int. Cl: Application Number: Lodged: 7/ f/ This doc:ument contains the amen-,dments made under Section 49 and is correct for printing.
Complete Specification-Lodged: Accepted: Lapsed: Published: Priority: *f I Related Art: i< s r TO BE COMPLETED BY APPLICANT Name of Applicant: Address of Applicant: Actual Inventor: Address for Service: JOHNSON JOHNSON PRODUCTS, INC. 501, George Street, NEW BRUNSWICK, NJ 08903, U.S.A. Richard John Wiggans Leslie James Squires and Rory James Maxwell Smith GRIFFITH HASSEL FRAZER 71 YORK STREET SYDNEY NSW 2000 AUSTRALIA Complete Specification for the invention entitled: ADHESIVE WOUND DRESSING The following statement is a full description of this invention, including the best method of performing it known to me/us:- 6092A:rk .1 _iii ADHESIVE WOUND DRESSING This invention relates to adhesive wound dressings, and more particularly to such dressings having a wound-contacting region formed from an alginate. The invention also relates to methods of making wound dressings. One known type of wound dressing comprises a thin plastics film which has an adhesive coating on one surface. This group of dressings includes the so-called occlusive dressings, by which is meant ,dressings which maintain the wound in a relatively moist state in which tissue repair is found to be enhanced. One form of occlusive dressing is that described in EP-A-0117632, and sold under the Trade Mark BIOCLUSIVE by Johnson Johnson. It consists of a thin polyurethane film (of the order of 35 to 44 o micron thickness), coated on one surface with an acrylic adhesive. An alternative, and well-known, form of dressing comprises an absorbent pad attached to an adhesive backing, which backing is often liquid permeable and, even when not liquid permeable, is usually highly permeable to moisture vapour. Such dressings are very commonly used for minor injuries and also in more serious cases when the volume of wound exudate is particularly large. We have now devised a dressing which combines the rapid healing advantages of occlusive dressings with the satisfactory management of wound exudate. According to the present invention, there is provided a wound dressing comprising a wound-contacting layer fixed to a substantially liquid impermeable plastics backing layer, the wound-contacting layer being formed from an alginate, GRIFFITH, HACK CO., SYDNEY, AUSTRALIA _LU ii and the backing layer extending beyond the edges of the wound-contacting layer to provide a marginal portion which is coated with adhesive. The ability of alginates to form haemostatic gels on coming into contact with body fluids is already known, but we have found that this property is of particular advantage in occlusive dressings. In some cases, fluid accumulation under an occlusive dressing can be troublesome, but the incorporation of an alginate layer in an occlusive dressing means that iv any fluid exuded by the wound is rapidly immobilised I by the alginate. The alginate may, for example, be calcium alginate, silver alginate, zinc alginate, sodium alginate, or mixtures thereof. Calcium alginate is particularly preferred, and is available from Courtaulds PLC, England. The alginate layer may conveniently be in the form of a pad of alginate fibres, such as fibres having a count in the range 1 decitex to 3.3 decitex. The preferred fibre length is from 10 to 100 mm, with a fibre length of from 25 to 75 mm being particularly preferred. When a fibrous alginate pad is used, it will usually be lightly bonded together to give a degree of integrity and resistance to delamination. This stabilisation can be achieved by any of a variety of means such as calendering, embossing or needling. The thickness of the pad will generally be in the range 0.1 mm to 6 mm, and preferably from 0.5 mm to 3 mm. It is particularly preferred that the pad be from 1 to 2 mm in thickness. The weight per unit area of the pad will usually be from 30 g/m 2 to 300 g/m 2 and preferably from 70 g/m 2 to 150 g/m 2 ~1 3 As an alternative to alginate fibres, alginates in powder form may be used. The thickness of the powder layer will generally be from 0.1mm to 0.75mm, and preferably from 0.05mm to 0.5mm. An average particle diameter of from 25 microns to 800 microns is preferred, with an average particle diameter in the range 50 microns to 400 microns being especially preferred. Although other alginates may be used if desired, the preferred powdered alginates are sodium alginate, calcium alginate, and mixtures thereof in any proportion. Suitable powdered alginates are available commercially from Kelco International, England. A further form of alginate which is suitable for use in the dressings of the present invention is an alginate film. Such a film may be formed by casting a solution of a water soluble alginate, e.g. sodium alginate, followed by drying. Optionally, additional absorbent materials such as sodium carboxymethyl cellulose may be included, e.g. in an amount of from 2% to 25% by weight. A preservative agent such as 2-bromo-2-nitro-l,3-propanediol may also be added, as may a plasticiser such as glycerol. The preservative, if included, will generally be present in an amount of from 0.1% to 1% by weight, while a suitable amount of plasticiser is from 2% to 25% by weight. Thus, a typical formulation, after drying, might be: II Sodium alginate Sodium carboxymethyl cellulose Preservative Glycerol 79.5% to 89.8% w/w 5% to 15% w/w 0.2% to 0.5% w/w 5% to 15% w/w The dried film thickness will generally be from 4 0.01 mm to 1.0 mm, and preferably from 0.05 mm to 0.25 mm. In a still further embodiment, the alginate may be in the form of a gel, generally from 0.01 to 2.0 mm in thickness. Such gels may suitably be formed by the controlled introduction of a suitable cation (e.g. calcium) into a solution of a water soluble alginate such as sodium alginate, preferably in the presence of a pH modifiei such as glucono delta lactone. The i alginate concentration may be, for example, from 2% to by weight and the final cation concentration may I suitably be from 0.2 to 10% by weight. Additional absorbents, plasticisers and preservatives may t optionally be included, as described above in relation to alginate films. The resultant gel will typically contain from 30% to 99% by weight of water, and it may Sthen be partially dried if desired, e.g. to a water I content of from 15% to 50%, and more preferably from I 20% to 40% by weight. A typical formulation might be Sodium alginate 5% to 15% w/w Sodium carboxymethyl cellulose 5% to 15% w/w Preservative 0.2% to 0.5% w/w Calcium phosphate 0.5% to 4% w/w Glycerol 5% to 15% w/w Glucono-S-lactone 0.5% to 4% w/w i Water to 100% Whichever form of alginate is chosen, it may optionally contain an antimicrobial agent, and it may also contain other haemostatic agents. In the case of proteinaceous haemostatic agents, such as collagen and thrombin, the alginate may be in the form of a complex with the haemostatic protein. Suitable protein/ alginate complexes are disclosed in EP-A-0140596. The plastics film used in the dressings of the present invention will usually be substantially impervious to liquids. The film may, for exa.ple, be a continuous film of a non-adherent water-impermeable polymer such as a polyolefin. Polyethylene and polypropylene are representative examples of this class, but polymers of higher olefins may of course be used, as may copolymers of two or more olefins, or copolymers of an olefin and one or more other S monomers. A suitable polyethylene film for use in the I ,dressings of the present invention is available from j t- Union Carbide Corporation under the Trade Mark UCAR, and a suitable polypropylene is available from British Cellophane Limited under the Trade Mark SHORCO. 'i Preferably, the film is impervious to liquids, II but has a moisture vapour permeability in the range 1000 g/m 2 /24hr to 3000 g/m 2 /24hr. Continuous I polyurethane films having such properties are available under the Trade Mark PLATILON from Plate Bonn GmbH., Bonn, W. Germany. The film is preferably from 10 to 200 micrometers in thickness, and more preferably from to 100 micrometers thick. For example, the film may be from 30 to 70 micrometers thick. The adhesive which is used for adhering the dressing to the patient is preferably an acrylic adhesive such as a copolymer of butyl acrylate and butyl methacrylate. It will usually be applied in an amount of from 20 g/m 2 to 50 g/m 2 and preferably from g/m 2 to 45 g/m 2 The size of the alginate pad will generally be related to the size of the dressing as a whole, but wide variations are possible. However, it is important that an adhesive coated margin of film surrounds the pad. This margin is preferably at least -6mm wide, and more preferably at least 20 mm wide. One difficulty associated with the attachment of layers of absorbent material having a low degree of coherence, such as powders or fibres, is that particles of the material tend to be shed and adhere to adjoining regions of the adhesive, where they impair adhesion of the dressing to the patient's skin. The present invention also provides an economical method for avoiding this difficulty. According to a second aspect of the present invention, there is provided a method of forming a S9 wound dressing comprising the steps of i) providing an adhesive-coated plastics film a o having a lamella releasably attached to its adhesive surface, ii) cutting the lamella into an inner and an e .outer portion, such that the outer portion ,surrounds the inner portion, iii) removing the inner portion to expose a region of the adhesive-coated plastics film, and iv) attaching a layer of absorbent material to said exposed region of film. In a particularly preferred embodiment, the outer portion of lamella is itself then removed in whole or in part to expose a further region of adhesive-coated film, to which may be attached one or more protective films to prevent soiling of the absorbent layer prior to use. Any part of the outer portion of lamella which is left in place for removal at the time of use of the dressing may be provided with a handling tab for ease of such removal. Similarly, if in the manufacture of the dressing a region of adhesive coated film is exposed and subsequently protected with a release 7 4 *1 I~I I tI t I S. I r.4 S 1 lamella, such release lamella is preferably also provided with a handling tab. The handling tab or tabs may be integral with the lamella, as in the BIOCLUSIVE dressing, but it is preferred that it or they be adhesively secured to the lamella, as disclosed in EP-A-0120570. A handling tab may also be secured to the inner portion of the lamella and to any part of the outer portion which is removed in the manufacturing process. Such handling tab or tabs will of course not be used by the end user of the dressing, but as an aid to manufacture. If it is desired to attach handling tabs to two adjacent portions of lamella, the following method is preferred. Firstly, a strip of handling tab material is attached to the lamella, bridging the intended line of cut separating the two portions of lamella. The handling tab material and the lamella are then cut simultaneously to provide a handling tab on each side of the line of cut. The release lamella may be formed from any of a wide variety of materials, but it will usually be formed from paper, from a plastics film, or from a combination of paper and plastics film. In order to provide ready release from the adhesive which will be used to adhere the dressing to the patient, the lamella, if formed from paper, will usually be coated with a silicone polymer in conventional manner. However, it is preferred that the outer-facing surface not be silicone-coated, so that it is receptive to adhesive for securing handling tabs. In practice, it is difficult to coat relatively lightweight paper with silicone on one surface only (because paper is somewhat permeable to the silicone), and it is therefore preferred to use a paper/plastics laminate 1 r~iI -8as the material of the lamella. Such paper/plastics laminates are substantially impermeable to silicone and can therefore readily be silicone-coated on only one surface. The non-coated surface, in addition to being receptive to the adhesive for the handling tabs, is also receptive to printing inks. The release lamellae of the dressings of the present invention can therefore be printed as desired. The handling tabs may be of the same material as the release lamella, or of different material. They may, for example, be of fabric or of uncoated paper. These materials have the advantage of giving better grip than the handling tabs of BIOCLUSIVE dressings which are, of necessity, silicone-coated. The adhesive which is used for securing handling tabs to the release lamella is preferably a hot-melt a1hesive such as a ethylene/vinyl acetate copolymer. One example of a suitable adhesive is that available under the Trade Mark INSTANT LOK from National Adhesives Resins Ltd. The adhesive is conveniently extruded onto the lamella in a strip from 1 mm to 5 mm wide, and from 0.5 g/m to 3 g/m. It will be appreciated, of course, that the adhesive can alternatively be applied to the handling tabs. The lamella can be cut into the desired separate portions, without cutting the plastics film, by techniques already known in the adhesive labels art, such as by die-stamping. As is well known in that art, it is more straightforward to cut through a soft material against a hard one than vice versa. However, the precision of modern die-cutting machinery (such as that made by Edale Engineering Ltd. of Budds Lane, Romsey, Hampshire, England) is such as to allow even a relatively hard release lamella to be cut without damaging the underlying, relatively soft, P plastics film. The critical requirement is that the release lamella be of closely defined thickness, so that the machine can be adjusted to cause the knives to penetrate just the thickness of the lamella and no further. The dressings of the present invention will usually be packaged in a hermetically-sealed envelope and sterilised, e.g with ethylene oxide or by S-irradiation. A wound dressing according to the present invention, and a method of making it, are now described by way of example, with reference to the accompanying drawings, in which:- Figure 1 is a schematic representation of a first stage in the manufacture of a dressing, Figure 2 is a schematic representation of a second stage in the manufacture of a dressing, t Figure 3 is a schematic representation of a third stage in the manufacture of a dressing, Figure 4 is a schematic representation of a fourth stage in the manufacture of a dressing, and Figure 5 is a schematic representation of the completed dressing. Referring to Figure 1, an adhesive-coated polyurethane film 11 is provided with a release paper 12. Two strips 13 of handling tab material are attached to the upper surface of release paper 12 by means of pairs of lines of adhesive 14. Figure 2 shows the dressing of Figure 1 after a first die-cutting step. Two lines of cut 15 between the lines of adhesive 14, separate the release paper into a central region 16 and two end regions 17. Each end region 17 now has a handling tab i8, while the central region 16 has two handling tabs 19. necessary to apply four separate strips 18, 18, 19, 19. 1 10 In an alternative method, the partially-formed dressing shown in Figure 2 may be formed by making the Sfirst ',Ie cut prior to applying the strips of handling tab material. In this case, of course, it is then i In a further variation, a narrow double sided pressure sensitive adhesive tape may be used instead of a line of holt melt adhesive. This method is preferred if either of the materials being bonded is temperature sensitive. Figure 3 shows the dressing of Figure 2 after a second die-cutting step. Two lines of cut 20 have now separated the central region 16 into an inner portion 21 and twc outer sections 22, each with respective pairs of handling tabs 23, 24. The inner portion 21 I may now easily be removed, to expose a region of adhesive-coated polyurethane film 11, to which is then attached a pad of absorbent material such as calcium Salginate fibre. The outer sections 22 and end regions S17 of the release paper act as a mask during this step to prevent particles of the pad material frcm i contaminating portions of the adhesive which are Download PDF in English

None